Becton, Dickinson and Company $BDX Shares Sold by Benjamin Edwards Inc.

Key Points

• Benjamin Edwards Inc. cut its stake in BDX by 66.5% in Q4, selling 92,545 shares and retaining 46,643 shares worth about $9.05M, while institutional investors own roughly 86.97% of the stock.
• Quarterly results showed EPS of $2.91 (beating $2.81) but revenue of $4.49B missed estimates of $5.15B; management set FY2026 guidance at $12.35–$12.65 EPS (analysts' consensus ~12.52).
• The board authorized a $10.0M share repurchase and declared a $1.05 quarterly dividend (annual $4.20, yield ~2.8%, ex-dividend June 9), while insiders have sold 1,102 shares in the last 90 days and now own 0.40% of the company.

Benjamin Edwards Inc. decreased its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 66.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,643 shares of the medical instruments supplier's stock after selling 92,545 shares during the quarter. Benjamin Edwards Inc.'s holdings in Becton, Dickinson and Company were worth $9,053,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BDX. Activest Wealth Management raised its holdings in Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company in the third quarter valued at approximately $25,000. Steph & Co. raised its holdings in Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 65 shares in the last quarter. Cornerstone Planning Group LLC increased its stake in Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 139 shares during the last quarter. Finally, Accredited Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 70 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 1,102 shares of company stock valued at $198,909. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $149.41 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The firm has a market cap of $42.54 billion, a PE ratio of 24.37, a price-to-earnings-growth ratio of 10.65 and a beta of 0.22. The company's 50 day simple moving average is $160.69 and its 200-day simple moving average is $181.92. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the firm posted $3.43 EPS. Becton, Dickinson and Company's quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 12.52 EPS for the current year.

Becton, Dickinson and Company declared that its board has authorized a share repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 68.52%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BDX shares. Wells Fargo & Company cut their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 10th. JPMorgan Chase & Co. lowered their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 10th. TD Cowen raised their target price on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a "hold" rating in a research report on Wednesday, February 11th. Jefferies Financial Group lowered their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating on the stock in a research report on Tuesday, February 10th. Finally, Argus lowered their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating on the stock in a research report on Monday, March 23rd. Six research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $189.08.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.